Condition
T-cell Large Granular Lymphocytic Leukemia
Total Trials
6
Recruiting
1
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
66.7%
-19.9% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
5Total
P 1 (3)
P 2 (2)
Trial Status
Completed2
Recruiting1
Not Yet Recruiting1
Terminated1
Unknown1
Trial Success Rate
66.7%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT07682792Phase 2Not Yet Recruiting
Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia
NCT05978141Recruiting
A Registry for People With T-cell Lymphoma
NCT05532722Phase 1CompletedPrimary
ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
NCT00076180Phase 1CompletedPrimary
Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia
NCT02742727Phase 1Unknown
CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma
NCT00278265Phase 2TerminatedPrimary
Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia
Showing all 6 trials